Dr. Richards on Urinary Tract Infections Associated With Worse Bladder Cancer Outcomes

Video

Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses the association between urinary tract infections (UTI) and worse bladder cancer outcomes in the Medicare population.

Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses a retrospective analysis of the association between urinary tract infections (UTI) and worse outcomes in patients with bladder cancer from a Medicare database analysis.

A recent study used Surveillance, Epidemiology, and End Results (SEER) Medicare data to examine a cohort of patients with bladder cancer. Researchers analyzed the symptoms patients presented with and if it was a hematuria or UTI claim, as well as the time frame from symptom presentation to diagnosis.

Researchers then went forward to examine the outcomes of these patients and if they varied, based on time of diagnosis and presented symptoms, Richards explains.

Data showed that women who presented with a UTI claim had worse pathology and survival outcomes compared to women with hematuria. There was a similar association with men enrolled in the study; however, the association was greater in women.

<<<

View more from the 2015 AUA Annual Meeting

Related Videos
Samer A. Srour, MB ChB, MS
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Samer A. Srour, MB ChB, MS
Samer A. Srour, MB ChB, MS
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
A panel of 5 experts on renal cell carcinoma
Chandler H. Park, MD, an expert on renal cell carcinoma
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Eric S. Christenson, MD
Benjamin Garmezy, MD